Have your own idea? Try our Stock Screener
U.S. Drug Retail Industry Analysis
UpdatedAug 08, 2025
DataAggregated Company Financials
Companies12
- 7D1.8%
- 3M2.1%
- 1Y8.6%
- YTDn/a
In the last week, the Drug Retail industry is up 1.9%, with Walgreens Boots Alliance up 2.2%. This takes the industry's 12 month performance to a gain of 8.6%. Looking forward, earnings are forecast to grow by 83% annually.
Industry Valuation and Performance
Has the U.S. Drug Retail Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 08 Aug 2025 | US$11.8b | US$158.0b | -US$6,422,794,849.13 | 77.3x | -1.8x | 0.07x |
| Sun, 06 Jul 2025 | US$11.4b | US$158.1b | -US$6,426,944,997.60 | 42.3x | -1.8x | 0.07x |
| Tue, 03 Jun 2025 | US$11.2b | US$155.4b | -US$5,907,846,595.74 | n/a | -1.9x | 0.07x |
| Thu, 01 May 2025 | US$11.1b | US$155.3b | -US$5,913,791,131.99 | n/a | -1.9x | 0.07x |
| Sat, 29 Mar 2025 | US$11.1b | US$153.8b | -US$8,968,800,570.33 | n/a | -1.2x | 0.07x |
| Mon, 24 Feb 2025 | US$10.1b | US$153.8b | -US$8,983,720,379.57 | n/a | -1.1x | 0.07x |
| Wed, 22 Jan 2025 | US$12.2b | US$153.8b | -US$8,983,621,124.60 | n/a | -1.4x | 0.08x |
| Fri, 20 Dec 2024 | US$9.9b | US$151.0b | -US$8,784,147,060.80 | n/a | -1.1x | 0.07x |
| Sun, 17 Nov 2024 | US$8.7b | US$151.0b | -US$8,795,001,728.35 | n/a | -1x | 0.06x |
| Tue, 15 Oct 2024 | US$9.1b | US$148.9b | -US$5,859,014,737.50 | 76.1x | -1.6x | 0.06x |
| Thu, 12 Sep 2024 | US$7.6b | US$147.8b | -US$5,892,333,216.13 | n/a | -1.3x | 0.05x |
| Sat, 10 Aug 2024 | US$9.5b | US$147.8b | -US$5,884,430,161.58 | n/a | -1.6x | 0.06x |
| Mon, 08 Jul 2024 | US$9.8b | US$147.8b | -US$5,905,473,897.34 | n/a | -1.7x | 0.07x |
| Wed, 05 Jun 2024 | US$13.9b | US$146.9b | -US$6,130,775,840.15 | 38.5x | -2.3x | 0.09x |
| Fri, 03 May 2024 | US$15.1b | US$146.9b | -US$6,142,333,882.99 | 38.5x | -2.5x | 0.1x |
| Sun, 31 Mar 2024 | US$18.9b | US$146.9b | -US$6,125,070,448.86 | 35.5x | -3.1x | 0.1x |
| Tue, 27 Feb 2024 | US$18.3b | US$144.7b | US$499.5m | 32.6x | 36.6x | 0.1x |
| Thu, 25 Jan 2024 | US$19.7b | US$144.7b | US$444.9m | 36.8x | 44.3x | 0.1x |
| Sat, 23 Dec 2023 | US$22.9b | US$141.4b | -US$3,209,348,662.00 | 50.1x | -7.1x | 0.2x |
| Mon, 20 Nov 2023 | US$18.6b | US$164.8b | -US$4,844,590,344.00 | 56x | -3.8x | 0.1x |
| Wed, 18 Oct 2023 | US$20.1b | US$141.3b | -US$3,213,485,995.00 | 361.3x | -6.2x | 0.1x |
| Fri, 15 Sep 2023 | US$19.3b | US$138.4b | -US$3,448,683,517.00 | 361.3x | -5.6x | 0.1x |
| Sun, 13 Aug 2023 | US$25.7b | US$138.3b | -US$3,450,626,683.00 | 361.3x | -7.5x | 0.2x |
| Tue, 11 Jul 2023 | US$26.1b | US$138.3b | -US$3,448,640,911.00 | n/a | -7.6x | 0.2x |
| Thu, 08 Jun 2023 | US$27.5b | US$135.5b | -US$3,271,729,200.00 | n/a | -8.4x | 0.2x |
| Sat, 06 May 2023 | US$28.1b | US$135.5b | -US$3,266,613,457.00 | n/a | -8.6x | 0.2x |
| Mon, 03 Apr 2023 | US$30.1b | US$135.5b | -US$3,264,805,695.00 | n/a | -9.2x | 0.2x |
| Wed, 01 Mar 2023 | US$30.9b | US$134.2b | -US$3,076,052,976.00 | n/a | -10.1x | 0.2x |
| Fri, 27 Jan 2023 | US$31.8b | US$134.3b | -US$3,077,363,146.00 | n/a | -10.3x | 0.2x |
| Sun, 25 Dec 2022 | US$33.6b | US$134.7b | US$4.2b | 7.7x | 8x | 0.2x |
| Tue, 22 Nov 2022 | US$35.4b | US$134.7b | US$4.2b | 8.1x | 8.4x | 0.3x |
| Thu, 20 Oct 2022 | US$29.2b | US$134.7b | US$4.2b | 6.7x | 6.9x | 0.2x |
| Sat, 17 Sep 2022 | US$30.0b | US$136.5b | US$5.0b | 5.8x | 6x | 0.2x |
| Mon, 15 Aug 2022 | US$35.4b | US$136.6b | US$5.0b | 6.9x | 7.1x | 0.3x |
Price to Earnings Ratio
7.1x
Current Industry PE
- Investors are pessimistic on the American Drug Retail industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading close to its 3-year average PS ratio of 0.14x.
Past Earnings Growth
- Total earnings for the Drug Retail industry have declined over the last three years, with the industry now making a loss overall.
- Meanwhile revenues have grown 5.0% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does U.S. Drug Retail compare with similar industries?
| US Market | 0.20% | |
| Consumer Staples | 3.16% | |
| Food and Staples Retail | 4.39% | |
| Drug Retail | 1.81% | |
| Big Box Super Stores | 4.87% | |
| Food Retail | 3.08% | |
| Food Distributors | -1.15% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| WBA Walgreens Boots Alliance | US$11.90 | 2.2% +US$225.0m | 9.6% | PS0.07x | |
| EMPG Empro Group | US$6.97 | 29.3% +US$13.7m | n/a | PE77.3x | |
| MGRX Mangoceuticals | US$1.84 | 9.5% +US$1.9m | -66.7% | PS42.5x | |
| RDGT Ridgetech | US$1.24 | 10.1% +US$667.5k | -40.2% | PS0.06x |